Oncologist

Information for Oncologists

Dako reagents have been your pathologist’s test-of-choice for over 30 years providing consistent reproducibility, high sensitivity in detecting early disease, and specificity for accurately defining a diagnosis.

The Dako demanding standards for clinical robustness means we are the industry leader with the most predictive tests for determining treatment decisions including: HercepTest and FISH HER2 for Herceptin, ER/PR for hormone Therapy, Topo2 for chemotherapy resistance therapy and cKIT for identifying GIST patients who will benefit from Gleevec.

Confidence in evidence based tests

Dako developed the first HER2 for selection of Herceptin patients and has over 10 years experience developing predictive diagnostics with FDA approved, clinical efficacy data guiding patient selection for drugs such as Herceptin, Gleevec, Erbitux, Tamoxifin and Chemotherapy regimens. Request Dako pharmacodiagnostics for clinically validated results.

Minimize delays for pathology reports

High quality Dako reagents minimize test re-runs delivering more rapid pathology reports to your desk. Oncologists can schedule patients sooner to begin treatment discussions with your patients. Dako products provide more prompt and definitive pathology reports, resulting in more responsive patient care.

Security in Reliable results

Dako has a long 35 year history of developing the highest quality cancer diagnostic tests with clinically validated results guiding oncologists to optimal treatment. All tests meet the most robust international standards for quality including: FDA standards for clinical accuracy, reproducibility, CE Mark, ISO13485. In addition, all Dako products receive strict quality testing prior to release to any pathology lab in the world.

Events

• 

  ESCCA 2013

  Nov 12, 2013 - Nov 14, 2013

• 

  SIAPEC National Pathology Conference

  Oct 26, 2013 - Oct 30, 2013

• 

  NSH 2013

  Sep 20, 2013 - Sep 25, 2013

• 

  APIAP 2013

  Sep 05, 2013 - Sep 08, 2013

• Events